This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Company News for Mar 12, 2025
by Zacks Equity Research
Companies in The News Are: FRG, ORCL, LEGN, PAY
PAYPositive Net Change ORCLPositive Net Change LEGNPositive Net Change FERGNegative Net Change
biotechnology computers
RHHBY Enters Into a $5.3B Deal With Zealand Pharma for Obesity Drug
by Zacks Equity Research
Roche has collaborated with Zealand Pharma to develop and commercialize petrelintide for obesity
RHHBYPositive Net Change NVOPositive Net Change LLYPositive Net Change
biotechnology medical pharmaceuticals
TSVT Up on Acquisition Agreement With BMY for $286 Million
by Zacks Equity Research
2seventy bio agrees to be acquired by partner BMY for $286 million. Shares gain.
REGNPositive Net Change BMYNegative Net Change NVOPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock Down 9% as CagriSema Misses Target in Second Obesity Study
by Zacks Equity Research
Novo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second phase III study, missing the guidance of 25%.
BMRNNegative Net Change NVOPositive Net Change GILDNegative Net Change CORTNegative Net Change
biotechnology biotechs medical pharmaceuticals
KOD Completes Enrollment in Phase III Study for Eye Disease Candidate
by Zacks Equity Research
Kodiak reports completing patient enrollment in its late-stage study evaluating tarcocimab for diabetic retinopathy.
BMRNNegative Net Change GILDNegative Net Change CORTNegative Net Change KODPositive Net Change
biotechnology biotechs medical pharmaceuticals
WK Kellogg (KLG) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
KLGNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Evertec (EVTC) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
EVTCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Bristol Myers Stock Gains 9.2% in a Month: Should You Buy Now or Wait?
by Ekta Bagri
BMY is banking on new drugs to offset generic competition for older drugs. However, this might not be enough as the outlook for 2025 is weak. We recommend investors to wait.
BMYNegative Net Change PFENegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies
by Zacks Equity Research
Incyte reports positive data from two phase III studies evaluating Opzelura for prurigo nodularis in adults.
BMRNNegative Net Change GILDNegative Net Change INCYPositive Net Change CORTNegative Net Change
biotechnology biotechs medical pharmaceuticals
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC
by Zacks Equity Research
The EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.
BMYNegative Net Change BMRNNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study
by Zacks Equity Research
Eli Lilly and INCY announce positive efficacy data from the late-stage alopecia study of baricitinib in adolescent patients.
BMRNNegative Net Change LLYPositive Net Change GILDNegative Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?
by Zacks Equity Research
KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
BMRNNegative Net Change GILDNegative Net Change KRYSPositive Net Change
biotechnology biotechs medical pharmaceuticals
SLDB Stock Rallies 60% in a Month: Here's What You Should Know
by Zacks Equity Research
Solid Biosciences stock soars 60% in a month after the company announced positive initial data from its phase I/II DMD study of SGT-003.
BIIBNegative Net Change RHHBYPositive Net Change SRPTNegative Net Change SLDBNegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More
by Zacks Equity Research
CMRX and JAZZ are in the spotlight this week following an acquisition agreement.
REGNPositive Net Change GSKPositive Net Change MRNANegative Net Change JAZZNegative Net Change
biotechnology biotechs medical pharmaceuticals
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
by Zacks Equity Research
EDIT stock is down following the announcement of dismal fourth-quarter 2024 results as both earnings and revenues miss estimates.
BMRNNegative Net Change GILDNegative Net Change VRTXNegative Net Change EDITNegative Net Change
biotechnology biotechs crispr gene-editing gene-therapy medical pharmaceuticals
EverQuote (EVER) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
EVERNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus
by Zacks Equity Research
FATE Therapeutics' Q4 loss and revenues improve year over year. Its innovative pipeline is in focus.
BMRNNegative Net Change GILDNegative Net Change FATENegative Net Change
biotechnology biotechs medical pharmaceuticals
New Strong Sell Stocks for March 6th
by Zacks Equity Research
ARTL, KW and KRP have been added to the Zacks Rank #5 (Strong Sell) List on March 6, 2025.
KWPositive Net Change KRPNegative Net Change ARTLNegative Net Change
biotechnology
Bayer Q4 Earnings In Line, Revenues Top on Nubeqa, Kerendia Sales
by Zacks Equity Research
BAYRY's fourth-quarter earnings match expectations. Revenues top estimates, driven by the strong performance of its pharmaceutical business.
REGNPositive Net Change JNJPositive Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
by Ahan Chakraborty
Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
New Strong Buy Stocks for March 5th
by Zacks Equity Research
PFLT, COMM, BGC, NLY and ACIU have been added to the Zacks Rank #1 (Strong Buy) List on March 5, 2025.
BGCNegative Net Change NLYNegative Net Change COMMNegative Net Change PFLTNegative Net Change ACIUNegative Net Change
biotechnology finance
Roche Gets FDA Approval for Acute Ischemic Stroke Drug for Adults
by Zacks Equity Research
RHHBY's member company, Genentech, obtains FDA nod for TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
RHHBYPositive Net Change BMRNNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
CytomX Gears Up to Report Q4 Earnings: What Should Investors Expect?
by Zacks Equity Research
On CTMX's fourth-quarter 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.
AMGNPositive Net Change CTMXNegative Net Change ACIUNegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
5 Stocks With Recent Price Strength Defying a Weak February
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are EVER, JAZZ, PGR, SONY, NWG.
PGRPositive Net Change JAZZNegative Net Change EVERNegative Net Change NWGPositive Net Change SONYNegative Net Change
biotechnology consumer-discretionary finance insurance
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)
by Zacks Equity Research
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
BMRNNegative Net Change GILDNegative Net Change FOLDNegative Net Change ACADNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals